We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

MiMedx Group Inc (MDXG) Common NPV

Sell:$7.51 Buy:$7.52 Change: $0.24 (3.10%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.24 (3.10%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.24 (3.10%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.

Contact details

1775 W Oak Commons Court, Ne
United States
+1 (770) 6519100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.14 billion
Shares in issue:
147.60 million
United States
US dollar

Key personnel

  • Joseph Capper
    Chief Executive Officer, Director
  • Douglas Rice
    Chief Financial Officer, Chief Accounting Officer
  • Ricci Whitlow
    Executive Vice President, Chief Operating Officer
  • William Hulse
    Chief Administrative Officer, General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.